Section Arrow
BLTE.NASDAQ
- Belite Bio
Quotes are at least 15-min delayed:2025/08/31 21:40 EDT
Regular Hours
Last
 63.03
-1.48 (-2.29%)
Day High 
64.625 
Prev. Close
64.51 
1-M High
74.49 
Volume 
17.20K 
Bid
62.98
Ask
63.61
Day Low
62.5 
Open
64 
1-M Low
60 
Market Cap 
2.12B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 64.39 
20-SMA 66.82 
50-SMA 63.43 
52-W High 86.53 
52-W Low 43.7 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.55/-2.14
Enterprise Value
2.12B
Balance Sheet
Book Value Per Share
4.57
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CARMCarisma Therapeutics0.215-0.013-5.70%-- 
TNFATNF Pharmaceuticals Inc.0.0483-0.0133-21.59%-- 
ADAPAdaptimmune Therapeutics plc0.0589-0.01-14.51%-- 
SRPTSarepta Therapeutics18.2-0.14-0.76%15.76PE
OTLKOutlook Therapeutics0.8512-0.2388-21.91%0.58PE
Quotes are at least 15-min delayed:2025/08/31 21:40 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.